Skip to main content

Spotlight on Denosumab in Postmenopausal Osteoporosis

BioDrugs volume 25, pages 261–264 (2011)Cite this article

Abstract

Denosumab (Prolia®) is a human recombinant monoclonal antibody that is approved for the treatment of postmenopausal osteoporosis in women at high or increased risk of fracture in the US, the EU, and several other countries. Denosumab has a novel mechanism of action; it binds to receptor activator of nuclear factor κB ligand and inhibits bone resorption by inhibiting osteoclast formation, function, and survival.

In postmenopausal women with osteoporosis, denosumab reduced the risk of vertebral, nonvertebral, and hip fractures compared with placebo over 3 years in the large, phase III FREEDOM study. In postmenopausal women with low bone mineral density (BMD) or osteoporosis, treatment with denosumab increased BMD and decreased markers of bone turnover more than alendronate in those who were essentially treatment-naive in the 1-year DECIDE study and also in the 1-year STAND study, in which women were switched from alendronate to denosumab or continued alendronate treatment. Denosumab was generally well tolerated in clinical trials, although long-term effects of very low bone turnover remain to be established.

Denosumab is administered once every 6 months via subcutaneous injection, which may be a preferred method of administration and may improve adherence to treatment compared with other osteoporosis treatments. Denosumab is a valuable new option for the treatment of postmenopausal osteoporosis in women at increased or high risk of fractures, and may be useful as a first-line treatment in women at increased risk of fractures who are unable to take other osteoporosis treatments.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Prolia™ (denosumab) injection, for subcutaneous use: US prescribing information. Thousand Oaks (CA): Amgen Inc., 2010

  2. Prolia 60 mg solution for injection in a pre-filled syringe: EU summary of product characteristics. Breda: Amgen Europe B.V., 2010 May 26

  3. Lewiecki EM. Treatment of osteoporosis with denosumab. Maturitas 2010 Jun; 66 (2): 182–6

    PubMed  Article  CAS  Google Scholar 

  4. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009 Feb; 24 (2): 182–95

    PubMed  Article  CAS  Google Scholar 

  5. Ominsky MS, Schroeder J, Jolette J, et al. Decreased bone turnover and porosity are associated with improved bone strength in ovariectomized (OVX) cynomolgus monkeys treated with denosumab, a fully human RANKL antibody [abstract no. S409]. J Bone Miner Res 2007 Sep 1; 22Suppl. 1: 126

    Google Scholar 

  6. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010 Oct; 25 (10): 2256–65

    PubMed  Article  CAS  Google Scholar 

  7. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010 Aug; 25 (8): 1886–94

    PubMed  Article  Google Scholar 

  8. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004 Jul; 19 (7): 1059–66

    PubMed  Article  CAS  Google Scholar 

  9. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009 Aug 20; 361 (8): 756–65

    PubMed  Article  CAS  Google Scholar 

  10. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009 Jan; 24 (1): 153–61

    PubMed  Article  CAS  Google Scholar 

  11. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010 Jan; 25 (1): 72–81

    PubMed  Article  CAS  Google Scholar 

  12. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008 Aug; 43 (2): 222–9

    PubMed  Article  CAS  Google Scholar 

  13. Kendler DL, Bessette L, Hill CD, et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 2010; 21: 837–46

    PubMed  Article  CAS  Google Scholar 

  14. Hiligsmann M, Reginster JY. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women. Bone 2010 Jul; 47 (1): 34–40

    PubMed  Article  CAS  Google Scholar 

  15. Jönsson B, Ström O, Eisman JA, et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011 Mar; 22 (3): 967–82

    PubMed  Article  Google Scholar 

  16. Strom O, Macarios D, Badamgarav E, et al. A UK denosumab cost-effectiveness model incorporating FRAX and adherence [abstract no. A09001963]. 31st Annual Meeting of the American Society for Bone and Mineral Research; 2009 Sep 11–15; Denver (CO)

  17. Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 2011; 28 (1): 63–82

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments and Disclosures

The full text article[17] from which this spotlight was derived was reviewed by: J.-P. Devogelaer, Service de Rhumatologie, Université Catholique de Louvain, Brussels, Belgium; D.A. Hanley, Departments of Medicine, Community Health Sciences, and Oncology Division of Endocrinology and Metabolism, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada; D.L. Kendler, Prohealth Clinical Research, University of British Columbia, Vancouver, British Columbia, Canada; M. Kleerekoper, Department of Internal Medicine, St Joseph Mercy Hospital, Ann Arbor, Michigan, USA; J.-Y. Reginster, Department of Public Health Sciences, University of Liege, Liege, Belgium.

The manufacturer of the agent under review was offered an opportunity to comment on the original article during the peer review process. Changes based on any comments received were made on the basis of scientific and editorial merit. The preparation of the original article and this spotlight was not supported by any external funding.

Author information

Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Marit D. Moen & Susan J. Keam

Authors
  1. Marit D. Moen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marit D. Moen.

Additional information

Adapted and reproduced from Drugs & Aging 2011; 28 (1): 63–82

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moen, M.D., Keam, S.J. Spotlight on Denosumab in Postmenopausal Osteoporosis. BioDrugs 25, 261–264 (2011). https://doi.org/10.2165/11207100-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11207100-000000000-00000

Keywords

  • Bone Mineral Density
  • Alendronate
  • Placebo Recipient
  • Denosumab
  • Risedronate